Royce & Associates’s Abiomed Inc ABMD Stock Holding History

Royce & Associates’s Portfolio ABMD Stock Details ABMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-2,000	Closed	-$818K	–	1236
2018 Q2	$818K	Sell	2,000 -8,000	-80%	-$2.9M	0.01%	976
2018 Q1	$2.91M	Hold	10,000	–	–	0.02%	746
2017 Q4	$1.87M	Sell	10,000 -10,000	-50%	-$1.87M	0.01%	867
2017 Q3	$3.37M	Hold	20,000	–	–	0.02%	697
2017 Q2	$2.87M	Buy	20,000 +3,000	+18%	+$403K	0.02%	753
2017 Q1	$2.13M	Buy	17,000 +7,000	+70%	+$811K	0.01%	841
2016 Q4	$1.13M	Buy	+10,000	New	+$1.16M	0.01%	921

Other funds holding ABMD

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

BCM

Brown Capital Management Baltimore, Maryland $500M AUM 25.3% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Royce & Associates's ABMD Position: Q3 2018 in Review

Royce & Associates sold out of Abiomed Inc (ABMD) in Q3 2018, closing a stake of 2,000 shares — an estimated $818K sold.

Royce & Associates first reported a position in ABMD in Q4 2016 and held it in 7 quarters. The position peaked at $3.37M in Q3 2017. 529 funds tracked by Wall St. Rank hold ABMD as of Q3 2018.

Royce & Associates reported no remaining Abiomed Inc position as of Q3 2018 after selling out during the quarter.
Royce & Associates sold 2,000 Abiomed Inc shares in Q3 2018, an estimated $818K.
Royce & Associates first reported a position in Abiomed Inc in Q4 2016 and held it in 7 quarters.
Royce & Associates's Abiomed Inc position peaked at $3.37M in Q3 2017.
529 funds tracked by Wall St. Rank held Abiomed Inc as of Q3 2018.

Based on Royce & Associates's 13F filing for Q3 2018, filed 13 Nov 2018.